EMERGENT BIOSOLUTIONS INC.
EBS US29089Q1058
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-53% | -75% | -80% | 269% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Zoon Kathryn C |
8.87 USD |
7,086 Sold |
62,853 USD |
15/08/2025 | 15/08/2025 |
Degolyer Donald W |
8.65 USD |
7,844 Sold |
67,831 USD |
12/08/2025 | 12/08/2025 |
Katkin Keith |
6.30 USD |
7,844 Sold |
49,417 USD |
23/05/2025 | 23/05/2025 |
Katkin Keith |
6.30 USD |
7,844 Sold |
49,417 USD |
23/05/2025 | 23/05/2025 |
Papa Joseph C CEO |
5.83 USD |
60,000 Bought |
349,800 USD |
13/05/2025 | 13/05/2025 |
Papa Joseph C CEO |
5.83 USD |
60,000 Bought |
349,800 USD |
13/05/2025 | 13/05/2025 |
Fowler Neal Franklin |
5.83 USD |
35,000 Sold |
204,050 USD |
12/03/2025 | 12/03/2025 |
Zoon Kathryn C |
5.73 USD |
10,000 Sold |
57,300 USD |
12/03/2025 | 12/03/2025 |
Degolyer Donald W |
10.91 USD |
25,000 Sold |
272,750 USD |
12/11/2024 | 12/11/2024 |
White Marvin L |
11.97 USD |
14,287 Sold |
171,015 USD |
11/11/2024 | 11/11/2024 |